Occupier

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board

06 Jan 2022

Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board OXFORD, UK – 6th January 2022 – Joanna Smart, an experienced Director and CEO in the life sciences sector has been appointed Non-Executive Chair of Oxford Cancer Biomarkers Ltd. She will take a leading role in helping the company achieve its growth and funding goals at a pivotal stage of the business, building on the two recent commercial launches of cancer... Read more

First Patient Dosed in Ground-Breaking Clinical Investigation for OxSonics Therapeutics

05 Jan 2022

First Patient Dosed in Ground-Breaking Clinical Investigation for OxSonics Therapeutics Oxford, UK – 5th January 2022 – OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, today announced that the first patient had been dosed in a first-in-human clinical investigation (ISRCTN17598292) evaluating its proprietary SonoTran® Platform. SonoTran is being evaluated in a... Read more

Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform

24 Dec 2021

Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform Agreement includes an upfront payment for four SENSIGHT subscriptions and associated professional services Oxford, U.K. – 24th December 2021 Sensyne Health plc (LSE:SENS or “the Company”) today announced a one-year agreement with Exscientia to leverage the deep learning AI capabilities of the Sensyne platform to study real-world... Read more

OrganOx receives FDA approval for metra device

20 Dec 2021

OrganOx receives FDA approval for metra device OrganOx, a world leader in normothermic machine perfusion (NMP), today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its metra system. The OrganOx metra is a fully automated NMP device for the preservation and transport of donor livers destined for transplantation. The marketing approval includes both livers... Read more

Sitryx appoints Tanya E. Borsuk, Ph.D., as Chief Business Officer

10 Nov 2021

Oxford, UK – 10 November 2021 – Sitryx (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-inflammation and immuno-oncology, today announces the appointment of Tanya E. Borsuk, Ph.D., as its Chief Business Officer. Tanya brings 15 years of strategic and scientific expertise across business development and corporate strategy. At Sitryx, Tanya will join the... Read more

News